
Study shows improvements in signs, symptoms after 3 months of treatment

Study shows improvements in signs, symptoms after 3 months of treatment

Cynthia Matossian, MD, FACS, advises on how ophthalmologists can start performing a better diagnosis of ocular surface disease in three simple steps.

Fast-acting efficacious options are key to treating acute inflammation

Cynthia Matossian, MD, FACS, explains why she believes if ophthalmologists consistently evaluate the ocular surface, tear film and lid margins—and treat any problems that we find—surgical outcomes will improve.

Surveyed patients express dissatisfaction with efficacy of eye drops.

Amid a surge in dry eye cases since reopening her practice during the ongoing pandemic, Lisa Nijm, MD, JD, shares how cyclosporine, a well-established form of treatment, poses both challenges and advantages for ophthalmologists.

Nanodrop technology improves lens comfort

Susan Coultas, PhD, and Preeya Gupta, MD, share their hopes for continued innovation in the ophthalmic space — including dry eye and retina — as well as the importance of the clinical research process.

Susan Coultas, PhD, and Preeya Gupta, MD, discuss Kala Pharmaceuticals’ dry eye product candidate in a poster presentation during the 2020 Women in Ophthalmology virtual summer symposium.

One ophthalmologist offers insight on how to help patients treat their dry eye symptoms when working from home amid the pandemic.

First new therapy in nearly a decade offers another option for physicians, patients













